Literature DB >> 15450251

Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system.

Günther Eissner1, Walter Kolch, Peter Scheurich.   

Abstract

The inflammatory cytokine tumor necrosis factor (TNF), as well as most other ligand members of the TNF superfamily, exist both as classical soluble cytokines, but also in the form of type II transmembrane proteins. Both forms possess bioactivity, although some effects are distinct. In addition, an increasing body of evidence suggests that the membrane integrated ligands can receive signals, i.e. act as receptors which can transmit positive and negative feedback signals into the ligand bearing cell. Thus, reverse signaling enables a two-way communication in cell-to-cell signaling, and it is conceivable that this bi-directional signal exchange contributes to the plasticity of the ligand-receptor systems. Reverse signaling mainly has been observed in the immune system and within the TNF superfamily. Its function is only beginning to emerge warranting additional investigation, especially when it comes to therapeutic strategies involving cytokine modulation. This review provides an update of the literature about reverse signaling of transmembrane TNF family members and discusses its potential biological and clinical impact.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15450251     DOI: 10.1016/j.cytogfr.2004.03.011

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  75 in total

Review 1.  Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease.

Authors:  Arnd Heiligenhaus; Stephan Thurau; Maren Hennig; Rafael S Grajewski; Gerhild Wildner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-08-25       Impact factor: 3.117

2.  CD70 Activation Decreases Pulmonary Fibroblast Production of Extracellular Matrix Proteins.

Authors:  Thi K Tran-Nguyen; Jianmin Xue; Carol Feghali-Bostwick; Frank C Sciurba; Daniel J Kass; Steven R Duncan
Journal:  Am J Respir Cell Mol Biol       Date:  2020-08       Impact factor: 6.914

3.  Cross-linking of CD137 ligand modulates immune responses of thioglycollate-elicited mouse peritoneal macrophages.

Authors:  Jun-Sang Bae; Hyeong-Sup Kim; Jae Hong Park; Sang-Hyuk Park; Hyeon-Woo Lee
Journal:  Inflamm Res       Date:  2010-12-24       Impact factor: 4.575

Review 4.  Sequence, structure, function, immunity: structural genomics of costimulation.

Authors:  Kausik Chattopadhyay; Eszter Lazar-Molnar; Qingrong Yan; Rotem Rubinstein; Chenyang Zhan; Vladimir Vigdorovich; Udupi A Ramagopal; Jeffrey Bonanno; Stanley G Nathenson; Steven C Almo
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

Review 5.  TNF-α, a good or bad factor in hematological diseases?

Authors:  Tian Tian; Min Wang; Daoxin Ma
Journal:  Stem Cell Investig       Date:  2014-06-01

Review 6.  The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games.

Authors:  Thomas Hehlgans; Klaus Pfeffer
Journal:  Immunology       Date:  2005-05       Impact factor: 7.397

7.  Tumour necrosis factor-alpha processing in interstitial lung disease: a potential role for exogenous proteinase-3.

Authors:  L Armstrong; S I H Godinho; K M Uppington; H A Whittington; A B Millar
Journal:  Clin Exp Immunol       Date:  2009-03-09       Impact factor: 4.330

Review 8.  Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents.

Authors:  Takahiko Horiuchi; Hiroki Mitoma; Shin-ichi Harashima; Hiroshi Tsukamoto; Terufumi Shimoda
Journal:  Rheumatology (Oxford)       Date:  2010-03-01       Impact factor: 7.580

9.  Bee venom attenuates neuroinflammatory events and extends survival in amyotrophic lateral sclerosis models.

Authors:  Eun Jin Yang; Jing Hua Jiang; Sang Min Lee; Sun Choel Yang; Hye Suk Hwang; Myeong Soo Lee; Sun-Mi Choi
Journal:  J Neuroinflammation       Date:  2010-10-15       Impact factor: 8.322

10.  Infliximab in the treatment of rheumatoid arthritis.

Authors:  A Perdriger
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.